Highlights in metastatic kidney cancer research from the 2023 International Kidney Cancer Symposium include promising data on zanzalintinib, a dose-finding study on belzutifan, and further ...

Patients who have metastatic chromophobe renal cell carcinoma (ChrRCC) that harbors sarcomatoid features (SF) benefited from immunotherapy (IO)-containing regimens vs patients wit ...

CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer. For patients with metastatic kidney cancer, a multidisciplinary approach ...

Metastasis-directed radiotherapy showed promising survival rates and low side effects in oligometastatic clear cell renal cell carcinoma. Median progression-free survival was 34 months, with a 3-year ...

Temporal patterns in renal cancer mortality: A 20-year analysis of US-Mexico border states. Cytoreductive nephrectomy for patients with metastatic non-clear cell renal cell carcinoma: Results from a ...

The prognostic utility of preoperative β2 microglobulin in patients with renal cell carcinoma. Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall ...

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective ...

Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 inhibition or ...

Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...

Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. Many patients with ...